Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Montpellier
Condition: Type 1 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 1
Study type: Interventional
Phase: Early Phase 1

Summary: 
      A single arm, single treatment study is proposed to assess the feasibility of a portable
      artificial pancreas system outside of a hospital based clinical research center.

      Adult T1DM patients will use a newly developed platform in conjunction with a subcutaneous
      insulin infusion pump and a continuous glucose monitor for 18 hours is quasi free conditions
      (hotel).
    

Detailed description: 
      Automated closed-loop control (CLC), known as "artificial pancreas" (AP) can have tremendous
      impact on the health and lives of people with type 1 diabetes (T1D). Our inter-institutional
      and international research team has been on the forefront of CLC developments since the
      beginning of the JDRF Artificial Pancreas initiative in 2006. Thus far, we have conducted
      three closed-loop control clinical trials (totaling 60 subjects with T1D), which demonstrated
      significantly more time in an acceptable "target" blood glucose range during CLC, and
      significantly fewer hypoglycemic events during CLC compared to open loop. Our overall
      objective is to sequentially test, validate, obtain regulatory approval for, and deploy at
      home, a closed-loop Control-to-Range (CTR) system comprised of two algorithmic components: a
      Safety Supervision Module (SSM) and an automated Range Correction Module (RCM). The SSM will
      monitor the safety of the subject's continuous subcutaneous insulin infusion pump (CSII) to
      prevent hypoglycemia, and will also monitor the integrity of continuous glucose monitor (CGM)
      data for signal sensor deviations or loss of sensitivity. The RCM will be responsible for the
      optimal regulation of postprandial hyperglycemic excursions through correction boluses.

      The first phase to address our overall objective is a pilot study that will test the ability
      of a cell-phone-based system to (1) run CTR in an outpatient setting, and (2) be remotely
      monitored. Specifically, this pilot study entails a hybrid hotel/hospital design targeting
      adults with T1D that are experienced insulin pump users. Subjects will spend one night in a
      local hotel, during which the phone-based system will be remotely monitored in an adjacent
      hotel room for validation that remote system monitoring can successfully occur. Subjects will
      spend the following day in the hospital, where CTR will be activated, and challenged with
      meals and a CGM sensor replacement . Subjects will then spend a second night in the hotel for
      continued evaluation of remote system monitoring, along with outpatient testing of the CTR
      system run on the phone-based system. This series of admissions will address the first major
      hurdles that need to be overcome for home deployment of a closed loop CTR system:

      Specific Aim 1: The phone-based CTR system can be remotely monitored by
      nurses/physicians/technicians to confirm appropriate functioning outside of the hospital
      setting.

      Specific Aim 2: The CTR can be deployed outside of the hospital setting.
    

Intervention name(s): portable artificial pancreas system with Control-To-Range algorithms
Intervention type(s): Device
Intervention description(s): The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
Intervention MeSH terms: Pancrelipase
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: Artificial Pancreas; Insulin Pump; Continuous Glucose Monitor; Closed Loop